Eli Lilly and Company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, the company's executive vice president and president of Lilly Cardiometabolic Health, will join a fireside chat at 3:20 p.m. Eastern time. The event will be available via live audio webcast on Lilly's investor website, with a replay accessible for about 90 days. This presentation highlights Lilly's ongoing commitment to advancing treatments in areas like diabetes, obesity, Alzheimer's, immune disorders, and cancer.
Eli Lilly announced that CVS Caremark will add its GLP-1 medications, including the new pill Foundayo and injection Zepbound, to their formularies starting next week. This move could allow millions of Americans to access these drugs if their employer...
Eli Lilly continues to outperform revenue expectations and is expanding its drug pipeline through strategic acquisitions in infectious diseases and other areas. While new infectious disease treatments like amezosvatein show promise, significant reven...
Novo Nordisk is gaining ground on Eli Lilly in the obesity drug market despite a 12.6% quarterly and 15% yearly drop in Ozempic sales to DKK 27.83 billion in Q1. The recent FDA approval of Wegovy HD, which matches Eli Lilly's Zepbound in weight-loss ...
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nord...
Eli Lilly announced that CVS Caremark will begin covering its obesity drug Foundayo starting June 1 and will resume coverage for Zepbound by October 1, making these treatments more accessible through major pharmacy benefit managers. Eligible patients...
